What Vetanic does

Vetanic Inc. is a Japanese biotech venture founded in January 2021, originating from joint research between Keio University and Nihon University, that develops regenerative medicine products for companion animals using proprietary induced pluripotent stem (iPS) cell technology. The company's core technology is a novel non-viral method for establishing clinical-grade animal iPS cells that overcomes pluripotency-induction resistance historically observed in dogs and other companion species, using a unique set of reprogramming factors introduced without viral vectors and an intermediate neural-stem-cell-like stage. Vetanic's flagship product is canine mesenchymal stem cells (ciMSC) differentiated from its proprietary canine iPS cells, targeting systemic inflammatory, autoimmune, and spinal cord injuries in dogs; the platform is also being extended to feline iMSC and equine iPS cells, with a world-first demonstration of canine iPSC-derived peripheral nerve cell differentiation. The company is pursuing Japan's first MAFF-approved veterinary regenerative medicine product under the Pharmaceutical and Medical Device Act, with products intended to be sold as standardized, donor-free (sourced from discarded canine placenta), cryopreserved cell therapy preparations distributed directly to veterinary hospitals upon approval.

Vetanic operates a B2B pharmaceutical distribution model: revenue will come from sale of approved cell therapy products to veterinary hospitals in Japan once MAFF approval is obtained, supplemented by a secondary revenue stream from regenerative medicine research reagents. The company holds an exclusive license to the foundational Japan Patent No. 7591219 (granted November 2024) and the international PCT/JP2020/016924 application, which together protect the core animal iPS cell establishment method. It has raised approximately 657.85 million yen (including capital reserve) through a 150 million yen seed round (July 2021), a 500 million yen Series A (August 2022), additional investment from Yokohama Next, and an April 2026 capital and business alliance with Sysmex Corporation and Kohjin Bio Co., Ltd. The company employs 1–10 staff at its headquarters in Hamamatsucho, Tokyo, and operates an R&D facility, the Shonan Lab, at Shonan Health Innovation Park in Fujisawa, Kanagawa. Co-founders include CEO Akinori Mochizuki (ex-Sosei Group CSO with ~30 years of pharmaceutical industry experience), CSO Prof. Kazuya Edamura (Nihon University), and CTO Prof. Seiji Shiozawa (Kurume University and Keio University).

Name

Vetanic

Legal name

株式会社Vetanic

Website

https://vetanic.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Vetanic is a Japan-based, university-launched biotech venture developing iPS cell-derived regenerative medicine products — starting with canine mesenchymal stem cells — for sale to veterinary hospitals upon regulatory approval by Japan's Ministry of Agriculture, Forestry and Fisheries.

Ownership category

akta.pro rank

Product category

Veterinary Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell & Gene Therapy for Veterinary Regeneration (HLAMANAD)

akta.pro secondary industries

Stem Cell Therapies (Autologous & Allogeneic) (HLAMANAA), Neurologic & Spinal Regeneration (HLAMANAH)

Keywords

• Veterinary regenerative medicine
• Animal iPS cells
• Canine stem cell therapy
• Cell therapy products
• Companion animal healthcare

Headquarters

HQ city

Hamamatsucho

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Veterinary Regenerative Medicine Product Sales: Revenue from the development, manufacturing, and sale of approved animal regenerative medicine products (cell therapy products) derived from iPS cells, including canine MSC products, sold to veterinary hospitals upon regulatory approval from MAFF under the PMD Act.
2. Regenerative Medicine Reagent Research Products: Research, development, manufacture and sale of reagents for regenerative medicine, as listed in the company's registered business description.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Vetanic develops and manufactures regenerative medicine products for animals using proprietary induced pluripotent stem (iPS) cell technology. The company's core offerings include clinical-grade canine iPS cells and canine mesenchymal stem cells (ciMSC) differentiated from those iPS cells, intended for use as licensed veterinary pharmaceutical cell therapy products targeting inflammatory, autoimmune, spinal cord injury and related conditions in companion animals. The company also supplies regenerative medicine research reagents for R&D use.

Product overview

Vetanic is a university-launched biotech venture specializing in regenerative medicine for animals using iPS cell technology. The company's core offering consists of proprietary clinical-grade canine iPS cells, from which canine mesenchymal stem cells (ciMSC) are differentiated for therapeutic applications. Vetanic operates a dual-product strategy: developing both regenerative medicine products for veterinary use (toward MAFF approval) and regenerative medicine research reagents. The company leverages patented virus-free iPS cell technology established through joint research with Keio University and Nihon University.

Differentiator

Problem solved

Functional benefit

Products and services

• Canine iPS Cells Proprietary clinical-grade canine induced pluripotent stem (iPS) cells developed through virus-free gene introduction with a unique set of reprogramming factors. The cells maintain pluripotency over long periods and are intended as the source material for clinical-grade veterinary regenerative medicine products.
• Canine Mesenchymal Stem Cells (ciMSC) Canine mesenchymal stem cells differentiated from Vetanic's proprietary canine iPS cells, developed as a cell therapy product compliant with the Pharmaceuticals and Medical Devices Act. Targeting systemic inflammatory diseases, autoimmune diseases, spinal cord injuries and related conditions in dogs.
• Regenerative Medicine Products for Veterinary Use Animal regenerative medicine products developed using Vetanic's iPS cell technology, targeting approval from Japan's Ministry of Agriculture, Forestry and Fisheries as qualified pharmaceutical products for veterinary use.
• Regenerative Medicine Research Reagents Research reagents for regenerative medicine research, development, manufacturing and sales.

Quantifiable outcome

• Nearly 90% of surveyed veterinarians expressed willingness to use an approved MSC preparation (regulatory-approved product)
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and supporting.

• Sysmex CorporationcoreTechnology or Integration · 1 April 2026Capital and business alliance with Sysmex Corporation (TSE Prime: 6869, Kobe, Hyogo) to advance veterinary regenerative medicine using iPS cell technology. Sysmex contributes advanced analytical technologies and quality control expertise to support Vetanic's cell therapy product development and manufacturing. A third-party share allotment was executed as the capital foundation of this alliance.
• Kohjin Bio Co., Ltd.coreTechnology or Integration · 1 April 2026Capital and business alliance with Kohjin Bio Co., Ltd. (TSE Growth: 177A, Sakado, Saitama) combining Vetanic's animal iPS cell technology with Kohjin Bio's custom culture media development capabilities. Prior to this alliance, a basic business partnership agreement was signed in November 2024 for product development and research reagent optimization. Kohjin Bio supports higher quality manufacturing and faster approval acquisition.
• Osaka Metropolitan University - Prof. Shingo Hatotani LaboratorysupportingStrategic or Co-development Partner · 5 December 2024Joint research agreement with Prof. Shingo Hatotani's research group at Osaka Metropolitan University Graduate School of Veterinary Medicine, Cell Pathology Laboratory. The group has independently established iPS cells from dogs and cats and achieved differentiation into blood lineage cells. This collaboration aims to accelerate social implementation of animal iPS cell technology and provide feedback to Vetanic's product development.
• Kohjin Bio Co., Ltd.coreTechnology or Integration · 11 November 2024Basic agreement signed for development of animal iPS cell-derived regenerative medicine products and animal regenerative medicine research-use products. Kohjin Bio provides expertise in cell culture media development, optimization, and kit development, as well as cell processing contract services, to accelerate Vetanic's R&D pipeline and support MAFF approval.
• Keio University - Prof. Hideyuki OkanocoreStrategic or Co-development PartnerTechnology co-founder and exclusive patent licensor. Prof. Okano's laboratory at Keio University Regenerative Medicine Research Center co-developed the foundational animal iPS cell technology. Vetanic holds exclusive ordinary license to the jointly filed patent (PCT/JP2020/016924).
• Nihon University - Prof. Kazuya EdamuracoreStrategic or Co-development PartnerTechnology co-founder and exclusive patent licensor. Prof. Edamura's laboratory at Nihon University Veterinary Surgery developed the canine iPS cell technology in collaboration with Keio University. Vetanic holds exclusive ordinary license to the jointly filed patent. Prof. Edamura serves as external director and CSO of Vetanic.
• Kurume University - Prof. Seiji ShiozawacoreStrategic or Co-development PartnerTechnology co-founder and exclusive patent licensor. Prof. Shiozawa's laboratory at Kurume University School of Medicine co-developed the animal iPS cell establishment method. Vetanic holds exclusive ordinary license to the jointly filed patent. Prof. Shiozawa serves as external director and CTO of Vetanic.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Elanco Animal Health: Major global animal health company (incl. former Aratana Therapeutics specialty therapeutics portfolio). Acquired a veterinary cell therapy platform and is a potential partner, acquirer, or competitor given Vetanic's eventual B2B distribution model.
• Nihon Zenyaku Kogyo (Zenoaq): Leading Japanese veterinary pharmaceutical company marketing a wide portfolio of companion-animal therapeutics. Comparable as a domestic Japanese vet-pharma distribution counterparty and possible commercialization partner for Vetanic's MAFF-approved products.
• Astellas Pharma: Major Japanese pharmaceutical company with regenerative medicine R&D. Comparable as a Japan-based strategic with the resources to in-license or partner around Vetanic's iPSC platform for cross-species translational development.

Emerging players

• ReproScience: Stem cell biotechnology company developing veterinary regenerative therapies, notably for spinal cord injury in dogs — the same indication Vetanic targets. Direct comparison in canine neuro-regeneration.
• Cynata Therapeutics: Australia-listed clinical-stage biotech whose Cymerus platform manufactures MSC from induced pluripotent stem cells — the same core technology stack (iPSC → MSC) Vetanic is applying in veterinary medicine. Relevant technology analogue.
• InGeneron: Clinical-stage regenerative medicine company enabling point-of-care autologous adipose-derived stem cell therapy in veterinary and human applications. Comparable in the regenerative medicine-for-animals category.
• Pluristem Therapeutics: Cell therapy company using placenta-derived adherent stromal cells (PLX cells) to produce off-the-shelf regenerative therapies. Comparable in its donor-free, placenta-sourced cell platform concept to Vetanic's placental canine MSC approach.

Direct peers

• MediVet (Vetoquinol): Animal health company offering in-clinic regenerative medicine kits (including stem cell therapy) for veterinary use. Now part of Vetoquinol, it competes directly in selling cell-based therapies to veterinary clinics.
• VetStem Biopharma: US-based pioneer in autologous adipose-derived stem cell therapy for dogs, cats, and horses. Closest comparable in delivering regenerative cell therapy products to companion animal hospitals, though it uses autologous rather than iPSC-derived allogeneic cells.
• Gallant: US-based biotech developing first FDA-approved ready-to-use stem cell therapy for companion animals, raising a large Series B to scale. Direct competitor in the licensed allogeneic veterinary regenerative medicine space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights8 records

Customer concentration

• LinkedInlinkedin.com/company/vetanic

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vetanic